Protein aggregation and ER stress

Brain Research

Volumn 1648, Issue , 2016, Pages 658-666

  Ogen Shtern, Navit ^a   Ben David, Tamuz ^a   Lederkremer, Gerardo Z ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; Huntington's disease; Neurodegenerative disease; Parkinson's disease; Protein misfolding; Unfolded protein response

Indexed keywords

PROTEASOME; UBIQUITIN;

DEGENERATIVE DISEASE; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; UNFOLDED PROTEIN RESPONSE; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN FOLDING; PROTEINOSIS;

ANIMALS; ENDOPLASMIC RETICULUM STRESS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN FOLDING;

EID: 84961918756     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2016.03.044     Document Type: Review

References (216)

1. Abdulkarim, B., et al. A missense mutation in PPP1R15B causes a syndrome including diabetes, short stature, and microcephaly. Diabetes 64 (2015), 3951–3962.
2. Abisambra, J.F., et al. Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J. Neurosci. 33 (2013), 9498–9507.
3. Aharony, I., et al. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Hum. Mol. Genet. 24 (2015), 2604–2614.
4. Al-Saif, A., Al-Mohanna, F., Bohlega, S., A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol. 70 (2011), 913–919.
5. Atkin, J.D., et al. Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. J. Biol. Chem. 281 (2006), 30152–30165.
6. Bai, X., et al. Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy. Pathobiol. Aging Age Relat. Dis., 5, 2015, 28743.
7. Balch, W.E., et al. Adapting proteostasis for disease intervention. Science 319 (2008), 916–919.
8. Behrends, C., et al. Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol. Cell 23 (2006), 887–897.
9. Bellucci, A., et al. Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease. J. Neurochem. 116 (2011), 588–605.
10. Bennett, E.J., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 448 (2007), 704–708.
11. Benyair, R., et al. Mammalian ER mannosidase I resides in quality control vesicles, where it encounters its glycoprotein substrates. Mol. Biol. Cell 26 (2015), 172–184.
12. Benyair, R., Ron, E., Lederkremer, G.Z., Protein quality control, retention, and degradation at the endoplasmic reticulum. Int. Rev. Cell Mol. Biol. 292 (2011), 197–280.
13. Benyair, R., Ogen-Shtern, N., Lederkremer, G.Z., Glycan regulation of ER-associated degradation through compartmentalization. Semin. Cell Dev. Biol. 41 (2015), 99–109.
14. Berk, J.L., et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310 (2013), 2658–2667.
15. Bernard-Marissal, N., et al. Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration. Brain 138 (2015), 875–890.
16. Bett, J.S., et al. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease. PLoS One, 4, 2009, e5128.
17. Biason-Lauber, A., et al. Loss of kinase activity in a patient with Wolcott-Rallison syndrome caused by a novel mutation in the EIF2AK3 gene. Diabetes 51 (2002), 2301–2305.
18. Bosco, D.A., et al. Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis. Cold Spring Harb. Perspect. Biol., 3, 2011, a007500.
19. Braakman, I., Hebert, D.N., Protein folding in the endoplasmic reticulum. Cold Spring Harb. Perspect. Biol., 5, 2013, a013201.
20. Breydo, L., Wu, J.W., Uversky, V.N., Alpha-synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta 1822 (2012), 261–285.
21. Brodsky, J.L., Cleaning Up: ER-Associated Degradation to the Rescue. Cell 151 (2012), 1163–1167.
22. Burrows, J.A., Willis, L.K., Perlmutter, D.H., Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Natl. Acad. Sci. USA 97 (2000), 1796–1801.
23. Caramelo, J.J., Parodi, A.J., Getting in and out from calnexin/calreticulin cycles. J. Biol. Chem. 283 (2008), 10221–10225.
24. Caramelo, J.J., Parodi, A.J., A sweet code for glycoprotein folding. FEBS Lett. 589 (2015), 3379–3387.
25. Carnemolla, A., et al. Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J. Biol. Chem. 284 (2009), 18167–18173.
26. Casas-Tinto, S., et al. The ER stress factor XBP1s prevents amyloid-β neurotoxicity. Hum. Mol. Genet. 20 (2011), 2144–2160.
27. Chiang, W.C., et al. Selective activation of ATF6 and PERK endoplasmic reticulum stress signaling pathways prevent mutant rhodopsin accumulation. Investig. Ophthalmol. Vis. Sci. 53 (2012), 7159–7166.
28. Cho, K.J., et al. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease. Neuroscience 163 (2009), 1128–1134.
29. Cleary, J.P., et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8 (2005), 79–84.
30. Colla, E., et al. Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J. Neurosci. 32 (2012), 3306–3320.
31. Colla, E., et al. Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. J. Neurosci. 32 (2012), 3301–3305.
32. Collinge, J., Human prion diseases and bovine spongiform encephalopathy (BSE). Hum. Mol. Genet. 6 (1997), 1699–1705.
33. Cooley, C.B., et al. Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proc. Natl. Acad. Sci. USA 111 (2014), 13046–13051.
34. Costa-Mattioli, M., et al. eIF2alpha phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. Cell 129 (2007), 195–206.
35. Credle, J.J., et al. alpha-Synuclein-mediated inhibition of ATF6 processing into COPII vesicles disrupts UPR signaling in Parkinson's disease. Neurobiol. Dis. 76 (2015), 112–125.
36. Das, I., et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science 348 (2015), 239–242.
37. Delepine, M., et al. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. 25 (2000), 406–409.
38. Dou, F., et al. Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. 100 (2003), 721–726.
39. Duennwald, M.L., Lindquist, S., Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes. Dev. 22 (2008), 3308–3319.
40. Eisenberg, D., Jucker, M., The amyloid state of proteins in human diseases. Cell 148 (2012), 1188–1203.
41. Ellgaard, L., Helenius, A., Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 4 (2003), 181–191.
42. Falsone, A., Falsone, S.F., Legal but lethal: functional protein aggregation at the verge of toxicity. Front. Cell. Neurosci., 9, 2015, 45.
43. Fang, L., et al. Mitochondrial function in neuronal cells depends on p97/VCP/Cdc48-mediated quality control. Front. Cell. Neurosci., 9, 2015, 16.
44. Fang, S., et al. The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA 98 (2001), 14422–14427.
45. Farrawell, N.E., et al. Distinct partitioning of ALS associated TDP-43, FUS and SOD1 mutants into cellular inclusions. Sci. Rep., 5, 2015, 13416.
46. Ferrante, R.J., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23 (2003), 9418–9427.
47. Ferreiro, E., et al. An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol. Dis. 23 (2006), 669–678.
48. Finkbeiner, S., Huntington's disease. Cold Spring Harb. Perspect. Biol., 3, 2011.
49. Finkbeiner, S., Mitra, S., The ubiquitin-proteasome pathway in Huntington's disease. Sci. World J. 8 (2008), 421–433.
50. Flierman, D., et al. Polyubiquitin serves as a recognition signal, rather than a ratcheting molecule, during retrotranslocation of proteins across the endoplasmic reticulum membrane. J. Biol. Chem. 278 (2003), 34774–34782.
51. Fonseca, A.C., et al. Loss of proteostasis induced by amyloid beta peptide in brain endothelial cells. Biochim. Biophys. Acta 1843 (2014), 1150–1161.
52. Fontaine, S.N., et al. Cellular factors modulating the mechanism of tau protein aggregation. Cell. Mol. Life Sci. 72 (2015), 1863–1879.
53. Fouillet, A., et al. ER stress inhibits neuronal death by promoting autophagy. Autophagy 8 (2012), 915–926.
54. Francardo, V., et al. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain 137 (2014), 1998–2014.
55. Gardner, B.M., et al. Endoplasmic reticulum stress sensing in the unfolded protein response. Cold Spring Harb. Perspect. Biol., 5, 2013, a013169.
56. Genereux, J.C., Wiseman, R.L., Regulating extracellular proteostasis capacity through the unfolded protein response. Prion 9 (2015), 10–21.
57. Godinho, B.M.D.C., et al. Delivering a disease-modifying treatment for Huntington's disease. Drug. Discov. Today 20 (2015), 50–64.
58. Gonzalez, M.A., et al. A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease. Brain 137 (2014), 2897–2902.
59. Gorbatyuk, M.S., et al. Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of Parkinson disease. Mol. Ther. 20 (2012), 1327–1337.
60. Gosavi, N., et al. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277 (2002), 48984–48992.
61. Gray, J.A., Fleet, D., Winblad, B., The need for thorough phase II. Stud. Med. Dev. Alzheimer's Dis. Alzheimers Res. Ther., 7, 2015, 67.
62. Gregori, L., et al. Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J. Biol. Chem. 270 (1995), 19702–19708.
63. Groisman, B., et al. Mannose trimming is required for delivery of a glycoprotein from EDEM1 to XTP3-B and to late endoplasmic reticulum-associated degradation steps. J. Biol. Chem. 286 (2011), 1292–1300.
64. Guedes-Dias, P., et al. HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neurons. Biochim. Biophys. Acta 1852 (2015), 2484–2493.
65. Gusella, J.F., MacDonald, M.E., Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. 1 (2000), 109–115.
66. Hall, A.A., et al. Sigma receptors suppress multiple aspects of microglial activation. Glia 57 (2009), 744–754.
67. Halliday, M., et al. Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell Death Dis., 6, 2015, e1672.
68. Hammond, C., Helenius, A., Folding of VSV G protein: sequential interaction with BiP and calnexin. Science 266 (1994), 456–458.
69. Han, D., et al. A kinase inhibitor activates the IRE1alpha RNase to confer cytoprotection against ER stress. Biochem. Biophys. Res. Commun. 365 (2008), 777–783.
70. Harding, H.P., et al. Transcriptional and translational control in the Mammalian unfolded protein response. Annu. Rev. Cell Dev. Biol. 18 (2002), 575–599.
71. Hardy, J., A hundred years of Alzheimer's disease research. Neuron 52 (2006), 3–13.
72. Hashimoto, K., Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog. Neurobiol. 100 (2013), 15–29.
73. Hassink, G., et al. TEB4 is a C4HC3 RING finger-containing ubiquitin ligase of the endoplasmic reticulum. Biochem. J. 388 (2005), 647–655.
74. Hatters, D.M., Putting huntingtin “aggregation” in view with windows into the cellular milieu. Curr. Top. Med. Chem. 12 (2012), 2611–2622.
75. Hayashi, T., Su, T.P., Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 131 (2007), 596–610.
76. Hebert, D.N., Molinari, M., In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol. Rev. 87 (2007), 1377–1408.
77. Herrera, F., et al. Visualization of cell-to-cell transmission of mutant huntingtin oligomers. PLoS Curr., 3, 2011, RRN1210.
78. Hetz, C., et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes. Dev. 23 (2009), 2294–2306.
79. Hetz, C., Mollereau, B., Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat. Rev. Neurosci. 15 (2014), 233–249.
80. Hetz, C., Chevet, E., Harding, H.P., Targeting the unfolded protein response in disease. Nat. Rev. Drug. Discov. 12 (2013), 703–719.
81. Hidvegi, T., et al. Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response. J. Biol. Chem. 280 (2005), 39002–39015.
82. Hipp, M.S., et al. Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease. J. Cell Biol. 196 (2012), 573–587.
83. Hipp, M.S., Park, S.H., Hartl, F.U., Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends Cell Biol. 24 (2014), 506–514.
84. Hirsch, C., et al. The ubiquitylation machinery of the endoplasmic reticulum. Nature 458 (2009), 453–460.
85. Holmberg, C.I., et al. Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J. 23 (2004), 4307–4318.
86. Hoozemans, J.J., et al. The unfolded protein response affects neuronal cell cycle protein expression: implications for Alzheimer's disease pathogenesis. Exp. Gerontol. 41 (2006), 380–386.
87. Hoozemans, J.J., et al. Activation of the unfolded protein response in Parkinson's disease. Biochem. Biophys. Res. Commun. 354 (2007), 707–711.
88. Hoozemans, J.J., et al. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am. J. Pathol. 174 (2009), 1241–1251.
89. Hosokawa, N., et al. EDEM1 accelerates the trimming of alpha1,2-linked mannose on the C branch of N-glycans. Glycobiology 20 (2010), 567–575.
90. Hosp, F., et al. Quantitative interaction proteomics of neurodegenerative disease proteins. Cell Rep. 11 (2015), 1134–1146.
91. Hyrskyluoto, A., et al. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-kappaB pathway. Cell Death Dis., 4, 2013, e646.
92. Itzhaki, R.F., et al. Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiol. Aging 25 (2004), 619–627.
93. Jahn, T.R., Radford, S.E., The Yin and Yang of protein folding. FEBS J. 272 (2005), 5962–5970.
94. Jaunmuktane, Z., et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature 525 (2015), 247–250.
95. Jiang, D., Niwa, M., Koong, A.C., Targeting the IRE1alpha-XBP1 branch of the unfolded protein response in human diseases. Semin. Cancer Biol. 33 (2015), 48–56.
96. Julier, C., Nicolino, M., Wolcott-Rallison syndrome. Orphanet J. Rare Dis., 5, 2010, 29.
97. Kamhi-Nesher, S., et al. A novel quality control compartment derived from the endoplasmic reticulum. Mol. Biol. Cell 12 (2001), 1711–1723.
98. Kaneko, M., et al. Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation. J. Neurosci. 30 (2010), 3924–3932.
99. Karagöz, G.E., et al. Hsp90-tau complex reveals molecular basis for specificity in chaperone action. Cell 156 (2014), 963–974.
100. Kay, C., et al. Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in huntington disease patients of european ancestry. Mol. Ther. 23 (2015), 1759–1771.
101. Kayed, R., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003), 486–489.
102. Keene, C.D., et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl. Acad. Sci. USA 99 (2002), 10671–10676.
103. Khalil, B., et al. PINK1-induced mitophagy promotes neuroprotection in Huntington's disease. Cell Death Dis., 6, 2015, e1617.
104. Kikis, E.A., Gidalevitz, T., Morimoto, R.I., Protein homeostasis in models of aging and age-related conformational disease. Adv. Exp. Med. Biol. 694 (2010), 138–159.
105. Kikkert, M., et al. Human HRD1 is an E3 ubiquitin ligase involved in degradation of proteins from the endoplasmic reticulum. J. Biol. Chem. 279 (2004), 3525–3534.
106. Kohler, C., Dinekov, M., Gotz, J., Granulovacuolar degeneration and unfolded protein response in mouse models of tauopathy and Abeta amyloidosis. Neurobiol. Dis. 71 (2014), 169–179.
107. Kokame, K., et al. Herp, a new ubiquitin-like membrane protein induced by endoplasmic reticulum stress. J Biol. Chem. 275 (2000), 32846–32853.
108. Kondratyev, M., et al. PERK-dependent compartmentalization of ERAD and unfolded protein response machineries during ER stress. Exp. Cell Res. 313 (2007), 3395–3407.
109. Kopito, R.R., Ron, D., Conformational disease. Nat. Cell Biol. 2 (2000), E207–E209.
110. Koppers, M., et al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 33 (2012), e7–13 837.
111. Kreft, S.G., Wang, L., Hochstrasser, M., Membrane topology of the yeast endoplasmic reticulum-localized ubiquitin ligase Doa10 and comparison with its human ortholog TEB4 (MARCH-VI). J. Biol. Chem. 281 (2006), 4646–4653.
112. Labbadia, J., et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J. Clin. Investig. 121 (2011), 3306–3319.
113. Labbadia, J., Morimoto, R.I., The biology of proteostasis in aging and disease. Annu. Rev. Biochem. 84 (2015), 435–464.
114. Lajoie, P., Snapp, E.L., Formation and toxicity of soluble polyglutamine oligomers in living cells. PLoS One, 5, 2010, e15245.
115. Lam, Y.A., et al. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97 (2000), 9902–9906.
116. Lamriben, L., et al. N-Glycan-based ER molecular chaperone and protein quality control system: the calnexin binding cycle. Traffic 17 (2016), 308–326.
117. Landwehrmeyer, G.B., et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol. 62 (2007), 262–272.
118. Lederkremer, G.Z., Glycoprotein folding, quality control and ER-associated degradation. Curr. Opin. Struct. Biol. 19 (2009), 515–523.
119. Lee, H., et al. IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux. Hum. Mol. Genet. 21 (2012), 101–114.
120. Lee do, Y., et al. Activation of PERK signaling attenuates Abeta-mediated ER stress. PLoS One, 5, 2010, e10489.
121. Leitman, J., et al. Compartmentalization of endoplasmic reticulum quality control and ER-associated degradation factors. DNA Cell Biol. 32 (2013), 2–7.
122. Leitman, J., et al. ER stress-induced eIF2-alpha phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin. PLoS One, 9, 2014, e90803.
123. Leitman, J., et al. Herp coordinates compartmentalization and recruitment of HRD1 and misfolded proteins for ERAD. Mol. Biol. Cell 25 (2014), 1050–1060.
124. Leitman, J., Ulrich Hartl, F., Lederkremer, G.Z., Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress. Nat. Commun., 4, 2013, 2753.
125. Lin, J.H., et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 318 (2007), 944–949.
126. Logue, S.E., et al. New directions in ER stress-induced cell death. Apoptosis 18 (2013), 537–546.
127. Lu, M., Boschetti, C., Tunnacliffe, A., Long term aggresome accumulation leads to dna damage, p53-dependent cell cycle arrest, and steric interference in mitosis. J. Biol. Chem. 290 (2015), 27986–28000.
128. Ma, T., et al. Suppression of eIF2alpha kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat. Neurosci. 16 (2013), 1299–1305.
129. Maattanen, P., et al. Protein quality control in the ER: the recognition of misfolded proteins. Semin. Cell Dev. Biol. 21 (2010), 500–511.
130. Malpass, K., Neurodegenerative disease: VCP mutations lead to defects in mitochondrial dynamics. Nat. Rev. Neurol., 9, 2013, 239.
131. Marrazzo, A., et al. Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. Neuroreport 16 (2005), 1223–1226.
132. Matsumoto, G., et al. Structural properties and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 aggregates. J. Cell Biol. 171 (2005), 75–85.
133. Maurice, T., et al. The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res. Brain Res. Rev. 37 (2001), 116–132.
134. McManus, R.M., et al. Respiratory infection promotes T cell infiltration and amyloid-beta deposition in APP/PS1 mice. Neurobiol. Aging 35 (2014), 109–121.
135. McNaught, K.S., Jenner, P., Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297 (2001), 191–194.
136. Messaed, C., Rouleau, G.A., Molecular mechanisms underlying polyalanine diseases. Neurobiol. Dis. 34 (2009), 397–405.
137. Miki, Y., et al. Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington's disease. Neurobiol. Dis. 74 (2015), 25–31.
138. Miranda, E., Romisch, K., Lomas, D.A., Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J. Biol. Chem. 279 (2004), 28283–28291.
139. Mitra, S., Tsvetkov, A.S., Finkbeiner, S., Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in huntington disease. J. Biol. Chem. 284 (2009), 4398–4403.
140. Moreno, J.A., et al. Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature 485 (2012), 507–511.
141. Nakatsukasa, K., Kamura, T., Brodsky, J.L., Recent technical developments in the study of ER-associated degradation. Curr. Opin. Cell Biol. 29c (2014), 82–91.
142. Nalbandian, A., et al. Targeted excision of VCP R155H mutation by Cre-LoxP technology as a promising therapeutic strategy for valosin-containing protein disease. Hum. Gene. Ther. Methods 26 (2015), 13–24.
143. Natsvlishvili, N., et al. Sigma-1 receptor directly interacts with Rac1-GTPase in the brain mitochondria. BMC Biochem., 16, 2015, 11.
144. Neugroschl, J., Sano, M., Current treatment and recent clinical research in Alzheimer's disease. Mt. Sinai J. Med. 77 (2010), 3–16.
145. Nguyen, L., et al. Role of sigma-1 receptors in neurodegenerative diseases. J. Pharmacol. Sci. 127 (2015), 17–29.
146. Ninagawa, S., et al. EDEM2 initiates mammalian glycoprotein ERAD by catalyzing the first mannose trimming step. J. Cell Biol. 206 (2014), 347–356.
147. Nishitoh, H., et al. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes. Dev. 22 (2008), 1451–1464.
148. Nunes, A.F., et al. TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-beta deposition in APP/PS1 mice. Mol. Neurobiol. 45 (2012), 440–454.
149. O'Connor, T., et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60 (2008), 988–1009.
150. Oakes, S.A., Papa, F.R., The role of endoplasmic reticulum stress in human pathology. Annu. Rev. Pathol. 10 (2015), 173–194.
151. Olivari, S., et al. EDEM1 regulates ER-associated degradation by accelerating de-mannosylation of folding-defective polypeptides and by inhibiting their covalent aggregation. Biochem. Biophys. Res. Commun. 349 (2006), 1278–1284.
152. Olzscha, H., et al. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144 (2011), 67–78.
153. Ortega, Z., Diaz-Hernandez, M., Lucas, J.J., Is the ubiquitin-proteasome system impaired in Huntington's disease?. Cell. Mol. Life Sci. 64 (2007), 2245–2257.
154. Park, S.W., Ozcan, U., Potential for therapeutic manipulation of the UPR in disease. Semin. Immunopathol. 35 (2013), 351–373.
155. Parodi, A.J., Mendelzon, D.H., Lederkremer, G.Z., Transient glucosylation of protein-bound Man9GlcNAc2, Man8GlcNAc2, and Man7GlcNAc2 in calf thyroid cells. A possible recognition signal in the processing of glycoproteins. J. Biol. Chem. 258 (1983), 8260–8265.
156. Pearce, M.M., et al. Prion-like transmission of neuronal huntingtin aggregates to phagocytic glia in the Drosophila brain. Nat. Commun., 6, 2015, 6768.
157. de Pedro-Cuesta, J., et al. Comparative incidence of conformational, neurodegenerative disorders. PLoS One, 10, 2015, e0137342.
158. Perlmutter, D.H., Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu. Rev. Med. 62 (2011), 333–345.
159. Petrucelli, L., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13 (2004), 703–714.
160. Polling, S., et al. Polyalanine expansions drive a shift into alpha-helical clusters without amyloid-fibril formation. Nat. Struct. Mol. Biol. 22 (2015), 1008–1015.
161. Prell, T., et al. The unfolded protein response in models of human mutant G93A amyotrophic lateral sclerosis. Eur. J. Neurosci. 35 (2012), 652–660.
162. Rabinovich, E., et al. AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. Mol. Cell Biol. 22 (2002), 626–634.
163. Raskin, J., et al. Neurobiology of Alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr. Alzheimer Res. 12 (2015), 712–722.
164. Ron, E., et al. Bypass of glycan-dependent glycoprotein delivery to ERAD by up-regulated EDEM1. Mol. Biol. Cell 22 (2011), 3945–3954.
165. Ross, C.A., Poirier, M.A., Protein aggregation and neurodegenerative disease. Nat. Med., 10, 2004 Suppl, S10-7.
166. Roth, D.M., et al. Modulation of the maladaptive stress response to manage diseases of protein folding. PLoS Biol., 12, 2014, e1001998.
167. Rothstein, J.D., Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 65:Suppl 1 (2009), S3–S9.
168. Roussel, B.D., et al. Unravelling the twists and turns of the serpinopathies. FEBS J. 278 (2011), 3859–3867.
169. Roussel, B.D., et al. Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol. 12 (2013), 105–118.
170. Sado, M., et al. Protective effect against Parkinson's disease-related insults through the activation of XBP1. Brain Res. 1257 (2009), 16–24.
171. Sasaki, S., Endoplasmic reticulum stress in motor neurons of the spinal cord in sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 69 (2010), 346–355.
172. Schaffar, G., et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 15 (2004), 95–105.
173. Scheper, W., Hoozemans, J.J., The unfolded protein response in neurodegenerative diseases: a neuropathological perspective. Acta Neuropathol. 130 (2015), 315–331.
174. Schroder, M., Kaufman, R.J., The mammalian unfolded protein response. Annu. Rev. Biochem. 74 (2005), 739–789.
175. Schulze, A., et al. The ubiquitin-domain protein HERP forms a complex with components of the endoplasmic reticulum associated degradation pathway. J. Mol. Biol. 354 (2005), 1021–1027.
176. Seidel, K., et al. Polyglutamine aggregation in Huntington's disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation. Neuropathol. Appl. Neurobiol., 2015.
177. Shao, J., Diamond, M.I., Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 16 (2007), R115–R123 Spec No. 2.
178. Shenkman, M., Eiger, H., Lederkremer, G.Z., Genesis of ER stress in huntington's disease. ER Stress Dis. 2 (2015), 94–106.
179. Shoulders, M.D., et al. Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep. 3 (2013), 1279–1292.
180. Sidrauski, C., et al. Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife, 2, 2013, e00498.
181. Silva, R.M., et al. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J. Neurochem. 95 (2005), 974–986.
182. Silverman, G.A., Pak, S.C., Perlmutter, D.H., Disorders of protein misfolding: alpha-1-antitrypsin deficiency as prototype. J. Pediatr. 163 (2013), 320–326.
183. Simmen, T., et al. PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. EMBO J. 24 (2005), 717–729.
184. Smith, H.L., Li, W., Cheetham, M.E., Molecular chaperones and neuronal proteostasis. Semin. Cell Dev. Biol. 40 (2015), 142–152.
185. Smith, S.E., et al. Activating transcription factor 6 limits intracellular accumulation of mutant alpha(1)-antitrypsin Z and mitochondrial damage in hepatoma cells. J. Biol. Chem. 286 (2011), 41563–41577.
186. Soejima, N., et al. Intracellular accumulation of toxic turn amyloid-beta is associated with endoplasmic reticulum stress in Alzheimer's disease. Curr. Alzheimer Res. 10 (2013), 11–20.
187. Sommer, T., Wolf, D.H., The ubiquitin-proteasome-system. Biochim. Biophys. Acta, 1843, 2014, 1.
188. Soto, C., Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4 (2003), 49–60.
189. Sun, X., Chen, W.D., Wang, Y.D., beta-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease. Front. Pharmacol., 6, 2015, 221.
190. Tabas, I., Ron, D., Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 13 (2011), 184–190.
191. Takahashi, T., et al. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum. Mol. Genet. 17 (2008), 345–356.
192. Tannous, A., et al. N-linked sugar-regulated protein folding and quality control in the ER. Semin. Cell Dev. Biol. 41 (2015), 79–89.
193. Taylor, J.P., Hardy, J., Fischbeck, K.H., Toxic proteins in neurodegenerative disease. Science 296 (2002), 1991–1995.
194. Tsaytler, P., et al. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 332 (2011), 91–94.
195. Um, J.W., et al. Parkin directly modulates 26S proteasome activity. J. Neurosci. 30 (2010), 11805–11814.
196. Urano, F., et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287 (2000), 664–666.
197. Vidal, R.L., et al. Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy. Hum. Mol. Genet. 21 (2012), 2245–2262.
198. Vieira, F.G., et al. Guanabenz treatment accelerates disease in a mutant SOD1 mouse model of ALS. PLoS One, 10, 2015, e0135570.
199. Walker, L.C., Jucker, M., Neurodegenerative diseases: expanding the prion concept. Annu. Rev. Neurosci. 38 (2015), 87–103.
200. Walsh, D.M., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002), 535–539.
201. Walther, D.M., et al. Widespread Proteome Remodeling and Aggregation in Aging C. elegans. Cell 161 (2015), 919–932.
202. Wear, M.P., et al. Proteins with Intrinsically Disordered Domains Are Preferentially Recruited to Polyglutamine Aggregates. PLS One, 10, 2015, e0136362.
203. Wei, H., et al. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum. Mol. Genet. 17 (2008), 469–477.
204. Weihl, C.C., et al. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum. Mol. Genet. 15 (2006), 189–199.
205. Wiley, J.C., Pettan-Brewer, C., Ladiges, W.C., Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. Aging Cell 10 (2011), 418–428.
206. Woerner, A.C., et al. Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. Science 351 (2016), 173–176.
207. Wolfe, K.J., Cyr, D.M., Amyloid in neurodegenerative diseases: friend or foe?. Semin. Cell Dev. Biol. 22 (2011), 476–481.
208. Yang, H., et al. Huntingtin interacts with the cue domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP. PLoS One, 5, 2010, e8905.
209. Ye, Y., Meyer, H.H., Rapoport, T.A., Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. J. Cell Biol. 162 (2003), 71–84.
210. Yu, M.S., et al. Beta-amyloid peptides induces neuronal apoptosis via a mechanism independent of unfolded protein responses. Apoptosis 11 (2006), 687–700.
211. Zamorano, S., et al. A BAX/BAK and cyclophilin D-independent intrinsic apoptosis pathway. PLoS One, 7, 2012, e37782.
212. Zapun, A., et al. Conformation-independent binding of monoglucosylated ribonuclease B to calnexin. Cell 88 (1997), 29–38.
213. Zheng, Z., Diamond, M.I., Huntington disease and the huntingtin protein. Prog. Mol. Biol. Transl. Sci. 107 (2012), 189–214.
214. Zielonka, D., Mielcarek, M., Landwehrmeyer, G.B., Update on Huntington's disease: advances in care and emerging therapeutic options. Park. Relat. Disord. 21 (2015), 169–178.
215. Zinszner, H., et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes. Dev. 12 (1998), 982–995.
216. Zuleta, A., et al. AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease. Biochem. Biophys. Res. Commun. 420 (2012), 558–563.